Iovance TIL Cell Therapy Solid Tumors 2021

Iovance Biotherapeutics presents its tumor infiltrating lymphocyte (TIL) cell therapy platform for treating solid tumors, highlighting clinical progress in metastatic melanoma, advanced cervical cancer, and non-small cell lung carcinoma. The presentation outlines the company's proprietary manufacturing process, over 400 patients treated, and pipeline programs combining TIL therapy with immune-checkpoint inhibitors.